Avastin/Lucentis/Eylea ruling good news for patients, says RPS

 Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:

“This is a landmark ruling and good news for patients and the NHS.

 “Avastin is licensed as a cancer treatment in the UK because the manufacturer has not sought a licence for any other purpose.  

“Avastin has been shown through real world evidence to be a safe and effective for treatment for age related wet macular degeneration. The additional bonus is that it saves the NHS a significant amount of money, which can then be used to help other patients.

“Patients should always be involved in decision-making around the medicines they take whenever possible.”